InflaRx NV
IF0
Company Profile
Business description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Contact
Winzerlaer Strasse 2
Jena07745
DEUT: +49 3641508180
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
74
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.70 | 56.70 | 0.65% |
| CAC 40 | 7,737.93 | 75.34 | 0.98% |
| DAX 40 | 23,774.47 | 101.18 | 0.43% |
| Dow JONES (US) | 44,446.42 | 48.52 | -0.11% |
| FTSE 100 | 8,765.77 | 19.56 | -0.22% |
| HKSE | 24,221.41 | 149.13 | 0.62% |
| NASDAQ | 20,352.47 | 149.58 | 0.74% |
| Nikkei 225 | 39,762.48 | 223.85 | -0.56% |
| NZX 50 Index | 12,784.29 | 49.76 | 0.39% |
| S&P 500 | 6,210.96 | 12.95 | 0.21% |
| S&P/ASX 200 | 8,597.70 | 56.60 | 0.66% |
| SSE Composite Index | 3,454.79 | 2.95 | -0.09% |